tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

TRDA Stock Latest News

Entrada Therapeutics expects cash to fund requirements through 2Q26
The FlyEntrada Therapeutics expects cash to fund requirements through 2Q26
2M ago
TRDA
Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)
PremiumThe Fly
Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)
2M ago
TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
2M ago
TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
PremiumPress Releases
Entrada Therapeutics to Present at Upcoming Investor Conferences
3M ago
TRDA
‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks
PremiumStock Analysis & Ideas
‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks
3M ago
BFH
COIN
Entrada Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyEntrada Therapeutics initiated with an Outperform at Oppenheimer
4M ago
TRDA
VRTX
Entrada Therapeutics promotes Dowden to President
PremiumThe Fly
Entrada Therapeutics promotes Dowden to President
4M ago
TRDA
Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
PremiumThe Fly
Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
5M ago
TRDA
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
PremiumPress Releases
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
5M ago
TRDA
Entrada completes dosing for first, second cohorts Phase 1 ENTR-601-44-101
PremiumThe Fly
Entrada completes dosing for first, second cohorts Phase 1 ENTR-601-44-101
5M ago
TRDA
Entrada Therapeutics expects cash to fund requirements through 2025
PremiumThe Fly
Entrada Therapeutics expects cash to fund requirements through 2025
6M ago
TRDA
Entrada Therapeutics reports Q3 EPS $1.02, consensus (74c)
PremiumThe Fly
Entrada Therapeutics reports Q3 EPS $1.02, consensus (74c)
6M ago
TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
PremiumPress ReleasesEntrada Therapeutics to Present at Upcoming Investor Conferences
7M ago
TRDA
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
PremiumPress Releases
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
7M ago
TRDA
Entrada announces first patient dosed in Phase 1 trial of ENTR-601-44
PremiumThe Fly
Entrada announces first patient dosed in Phase 1 trial of ENTR-601-44
7M ago
TRDA
Entrada Therapeutics awards funding to non-profit organizations
PremiumThe Fly
Entrada Therapeutics awards funding to non-profit organizations
8M ago
TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
PremiumPress Releases
Entrada Therapeutics to Present at Upcoming Investor Conferences
8M ago
TRDA
Entrada Therapeutics appoints Chapman to its board of directors
PremiumThe Fly
Entrada Therapeutics appoints Chapman to its board of directors
9M ago
TRDA
Entrada Therapeutics reports Q2 EPS (78c), consensus (69c)
PremiumThe Fly
Entrada Therapeutics reports Q2 EPS (78c), consensus (69c)
9M ago
TRDA
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
PremiumPress ReleasesEntrada Therapeutics Reports Second Quarter 2023 Financial Results
9M ago
TRDA
Entrada receives authorization in the UK for Phase I trial of ENTR-601-44
PremiumThe Fly
Entrada receives authorization in the UK for Phase I trial of ENTR-601-44
9M ago
TRDA
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
PremiumPress Releases
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
11M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >